WALTHAM, Mass.--(BUSINESS WIRE)--Repligen Corporation (NASDAQ: RGEN) today reported results for the first quarter of fiscal year 2012, ended June 30, 2011. Total revenue for the first quarter was $7,654,000 compared to total revenue of $7,010,000 for the first quarter of fiscal year 2011, an increase of $644,000 or 9%. Bioprocessing product revenue for the first quarter was $4,358,000 compared to $4,269,000 for the first quarter of fiscal year 2011. Royalty and research revenue for the first quarter, consisting primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia®, was $3,295,000 compared to $2,741,000 for the first quarter of fiscal 2011. This increase in royalty and research revenue is largely due to an increase in Orencia® sales as well as an increase in research grants which offset research and development expenses.
